Core Viewpoint - The approval of the supplemental new drug application for ADASUVE® by the FDA marks a significant regulatory milestone for the company, facilitating the commercial production of the product in the U.S. [1][2] Group 1: FDA Approval and Production - The FDA approved the supplemental new drug application for ADASUVE® on December 29, 2025, allowing the commercial production facility to be relocated from Mountain View, California, to Fremont, California [1] - The application was originally submitted to the FDA on August 29, 2025, by the previous owner, and the company's wholly-owned subsidiary, Nova Pneuma Incorporated (NPI), acquired the relevant assets in December 2025 [1] Group 2: Strategic Implications - The FDA approval signifies the completion of regulatory requirements associated with the company's first pharmaceutical facility acquisition in the U.S. [2] - The board believes this approval supports the company's strategy to expand its innovative drug delivery technology portfolio based on the Staccato® platform, which has the potential for application in various therapeutic indications [2]

Core Viewpoint - The company has entered into an asset purchase agreement to acquire assets related to Alexza Pharmaceuticals for a total consideration of $15 million, which aligns with its strategy to expand its innovative drug delivery technology portfolio and global outreach [1][2]. Group 1: Acquisition Details - The buyer, Nova Pneuma Incorporated, a wholly-owned subsidiary of the company, will acquire all assets related to Alexza's business, including properties, equipment, materials, patents, and other intellectual property [1]. - The total purchase price for the assets is set at $15 million [1]. Group 2: Strategic Alignment - The acquisition supports the company's strategy to expand its product portfolio through the Staccato® platform, which has a wide range of therapeutic potential [2]. - The assets acquired are expected to complement the existing product pipeline and create synergies [2]. - The agreement with UCB, a leading biopharmaceutical company in the epilepsy treatment field, marks a significant milestone in the company's global expansion strategy [2].